Not yet recruiting NCT07623057
A Study Testing the Safety and Effects of FB102 in Healthy Volunteers
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: FB102 Single dose, FB102 Multiple doses, FB102 Placebo.
- Who it may be relevant to
- Registry conditions: Healthy Volunteer. Basic parameters: 18 years — 60 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Australia
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Phase 1, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity After Single and Multiple Dose Administration of FB102 Administered in Healthy Participants
Overview
The purpose of this Phase 1 trial is to evaluate the safety and effects of FB-102 in healthy volunteers following single and multiple doses.
Detailed description
FB-102 will be administered as either a single dose (Part A) or multiple doses (Part B), compared with a placebo control.
Part A (single ascending dose, SAD), participants will receive single dose FB102 will be administered as a single dose.
Part B (multiple ascending dose, MAD), participants will receive multiple doses of FB-102 or placebo.
Interventions
- Drug FB102 Single dose
FB102 will be administered as a single dose - Drug FB102 Multiple doses
FB102 will be administered once weekly for 4 doses. - Drug FB102 Placebo
Matching placebo identical to FB102 formulation but without the active pharmaceutical ingredient
Primary outcome measures
- Incidence, severity, and relationship to treatment of treatment-emergent adverse events (TEAEs) [Time frame: From day 1 to Day 85 (End of treatment visit)]
- Incidence, severity, and relationship to treatment of SAEs [Time frame: From day 1 to Day 85 (End of treatment visit)]
Secondary outcome measures (4)
- Plasma PK parameters for single dose- maximum serum concentration (Cmax) [Time frame: Day 1,2,3,4,5,8,15,22,36,50,85]
- Plasma PK parameters for single dose- time to maximum concentration (Tmax) [Time frame: Day 1,2,3,4,5,8,15,22,36,50,85]
- Plasma PK parameters for Multiple dose- maximum serum concentration (Cmax) [Time frame: Days 1 and 22]
- Plasma PK parameters for Multiple dose- time to maximum concentration (Tmax) [Time frame: Days 1 and 22]
Eligibility criteria
Inclusion criteria
- Body mass index (BMI) between 18.0 and 32.0 kg/m2, inclusive, at Screening.
- Weight ≥50 kg and ≤100kg.
- Men are required to agree to practice true abstinence; be surgically sterilized (performed at least 6 months prior and documented to no longer produce sperm - verbal confirmation through medical history review acceptable); or agree to use a condom plus effective contraception for their female partner if of childbearing potential, from Screening and for at least 90 days after the EOT visit and refrain from donating sperm during this period. Effective contraception includes established use of hormonal contraception beginning at least 30 days prior to the Screening visit; or placement of an intrauterine device or intrauterine system. These contraception requirements do not apply if the male participant is in an exclusively same sex relationship; sperm donation prohibitions apply.
- Women are eligible to participate if they are not pregnant, not breastfeeding, and at least 1 of the following conditions apply:
- Not of childbearing potential, defined as surgically sterile (hysterectomy, bilateral salpingectomy, tubal ligation or bilateral oophorectomy - verbal confirmation through medical history review is acceptable).
- Postmenopausal (no menses for 12 months and confirmed by follicle-stimulating hormone \[FSH\] level ≥40 mlU/mL).
- Of childbearing potential and agree to practice true abstinence or agree to use a highly effective method of contraception consistently from 30 days prior to the Screening visit until the EOT visit and are required to agree not to donate ova during the trial and for 90 days after the EOT visit.
Exclusion criteria
- Any clinically significant medical condition malignancy allergy infection or immunosuppressive condition as determined by the Investigator except cured basal or squamous cell skin cancer.
- Alkaline phosphatase (ALP), aspartate transaminase (AST), alanine transaminase (ALT), and/or total bilirubin >1.5× the upper limit of normal (ULN). Participants with bilirubin >2× ULN that have a documented diagnosis of Gilbert's syndrome can be enrolled at the Investigator's discretion.
- History of malignancy of any organ system (other than localized basal cell carcinoma of the skin or in situ cervical cancer considered treated and cured), treated or untreated, within 5 years before Screening, regardless of whether there is no evidence of local recurrence or metastases.
- Positive for hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (HCV) antibodies, anti-human immunodeficiency virus (HIV) 1 and 2 antibodies, or interferon-gamma release assay (IGRA) for tuberculosis.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple blind
- Primary purpose
- Treatment
Study locations
Australia · 1 center
- University of Sunshine Coast, Morayfield — Eastwood
Identifiers
NCT: NCT07623057 · FB102-102